What question did this study set out to answer?

This research aims to evaluate the effectiveness of tofacitinib in managing cardiac sarcoidosis, particularly in reducing the need for corticosteroids.

April 3, 2026Open Heart0 citationsOpen Access

Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management

LFLukas Frischknecht MSMelina Stüssi-Helbling YTYuan Tian

Key Points

This research aims to evaluate the effectiveness of tofacitinib in managing cardiac sarcoidosis, particularly in reducing the need for corticosteroids.
Evaluated eight patients with treatment-refractory cardiac sarcoidosis
Monitored changes in myocardial inflammation
Assessed corticosteroid dependency levels
Seven out of eight patients showed significant reduction in myocardial inflammation
Most patients reduced their corticosteroid dependency
Indicates potential for tofacitinib in complex patient management

Abstract

Tofacitinib shows promising results in managing treatment-refractory CS, with seven out of eight patients achieving significant reduction in myocardial inflammation and corticosteroid dependency. However, further studies with larger prospective cohorts are essential to solidify these findings and assess the drug's efficacy and safety profile in this complex patient group.

AI से पूछें

Bookmark

View Full Paper